PhRMA Testing Pilot Framework For Structured Benefit-Risk Assessment
Executive Summary
The Pharmaceutical Research and Manufacturers of America’s Benefit-Risk Action Team expects to complete pilot testing of a framework for conducting benefit-risk assessments by the end of 2011.
You may also be interested in...
Benefit-Risk Assessments For Me-Too Drugs Encouraged By FDA
Sponsors should complete agency’s structured benefit-risk framework to help reviewers better understand the reason the product is needed in the marketplace.
FDA’s Benefit-Risk Framework Should Be Used Earlier In Development, Firms Say
Early discussions based on the framework could engender more efficient drug reviews and aid industry in decisions on clinical programs, BIO and PhRMA note in comments to the agency.
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
Drug reviews will include a benefit-risk summary assessment that states the rationale for regulatory action on a drug or biologic application and explains how differences of opinion among reviewers were resolved.